October 2026 leaves most acne routines intact but widens access and eases follow-up rules. Prescription-strength combinations moved over the counter, isotretinoin checks got simpler, and a new oral drug posted year-long results. A routine here means your daily sequence of cleanser, leave-on treatment, moisturizer, and sunscreen. Small regulatory shifts matter because they decide what you can buy, how often you must test, and which options your clinician can offer next.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Can you get a retinoid combination without a prescription?
- Did isotretinoin monitoring get simpler?
- Should benzoyl peroxide stay in your routine?
- What new pill is worth watching?
Can you get a retinoid combination without a prescription?
Galderma received Food and Drug Administration approval to sell Differin Epiduo Gel over the counter for ages 12 and older. The product combines adapalene 0.1% plus benzoyl peroxide 2.5% in one fixed dose, meaning two actives in a single formula. Galderma described the change in its FDA approval notice on May 22, 2026.
The shift fits current American Academy of Dermatology guidance, which strongly recommends fixed-dose combinations alongside topical benzoyl peroxide, retinoids, and antibiotics. For shoppers, one tube can replace separate retinoid and benzoyl peroxide steps at night. Start on alternate nights, moisturize, and use morning sunscreen because retinoids raise sun sensitivity.
Did isotretinoin monitoring get simpler?
Isotretinoin is an oral drug reserved for severe acne and tracked in a strict safety program. The National Community Pharmacists Association reported Food and Drug Administration changes to the iPLEDGE safety program on Feb. 9, 2026, effective Aug. 9, 2026.
Prescribers can now authorize at-home pregnancy tests during and after treatment, and the update ends the 19-day lockout after a missed 7-day pickup window, according to the association summary. In the United Kingdom, the National Institute for Health and Care Excellence revised acne guideline NG198 on April 30, 2026. Recommendations 1.5.19-1.5.20 no longer require two independent clinicians to approve isotretinoin for under-18s. The institute links the change to removal of the prior regulatory requirement.
- Ask your prescriber whether home testing fits your plan
- Track pickup dates so you stay inside the 7-day window
- Confirm local age and consent rules before starting
Should benzoyl peroxide stay in your routine?
Food and Drug Administration testing of 95 benzoyl peroxide products found more than 90% had undetectable or very low benzene. Six lots from La Roche-Posay, Proactiv, Walgreens, SLMD and Zapzyt were voluntarily recalled at retail level in March 2025. Dermatology Advisor summarized the agency statement in December 2025. Acne Action Canada noted in February 2026 that the agency judged cancer risk very low even with decades of daily use.
Risk rises when tubes sit in heat because benzoyl peroxide can break down into benzene at high temperatures. American Academy of Dermatology guidance still strongly recommends benzoyl peroxide, topical retinoids, antibiotics, and fixed-dose combinations. It also supports oral doxycycline and oral isotretinoin for severe disease. Newer options such as clascoterone, sarecycline, and hormonal agents carry conditional recommendations tied partly to cost and access.
- Store products at the temperature printed on the label
- Keep tubes out of hot cars and away from heaters
- Throw out swollen, discolored, or foul-smelling product
What new pill is worth watching?
Sagimet Biosciences and partner Ascletis reported full 52-week results for once-daily oral denifanstat 50 mg in moderate-to-severe acne. About 57% reached treatment success with generally favorable tolerability. The companies presented the data at EADV 2026, as described in the trial results announcement.
Denifanstat is a first-in-class fatty-acid-synthase inhibitor for acne. The Food and Drug Administration issued a Study May Proceed letter on Aug. 13, 2026 for a United States Phase 3 AURORA trial. Almirall's sarecycline won China approval in January 2026, so ask your dermatologist about trial sites if standard routines fall short.